Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23515282 | 0.96 | FAAH (0.40) | FAAHNPC1RAB9ASIRT1CYP1A2 | |
| SCHEMBL24951185 | 0.92 | FAAH (0.39) | FAAHNPC1RAB9ASIRT1TAAR1 | |
| SCHEMBL21891750 | 0.88 | SIRT1 (0.43) | FAAHNPC1RAB9ASIRT1CYP1A2 | |
| SCHEMBL23423407 | 0.85 | SMN1; SMN2 (0.41) | FAAHNPC1RAB9ASIRT1CYP1A2 | |
| SCHEMBL21891818 | 0.85 | SIRT1 (0.52) | FAAHSIRT1 | |
| SCHEMBL21891778 | 0.85 | ITGB1 (0.49) | NPC1RAB9ATAAR1GAA | |
| SCHEMBL23515293 | 0.84 | NPC1 (0.41) | FAAHNPC1RAB9ATAAR1GAA | |
| SCHEMBL23130277 | 0.84 | SIRT1 (0.56) | FAAHSIRT1 | |
| SCHEMBL21891776 | 0.84 | CTSK (0.45) | NPC1RAB9ASIRT1CYP1A2TAAR1 | |
| SCHEMBL21802411 | 0.84 | SIRT1 (0.56) | FAAHSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021574-A1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11352319-B2 | Method for producing carbamate and method for producing isocyanate | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20210179548-A1 | METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-06-17 | — | — | US | disclosed |
| WO-2021100131-A1 | METHOD FOR PRODUCING ISOCYANATE | 旭化成株式会社 | 2021-05-27 | — | — | WO | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352319-B2 | Method for producing carbamate and method for producing isocyanate | CPS1, CA7, CA4 | FAAH 563/4885NPC1 2143/4885RAB9A 3532/4885 |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | FAAH 847/4885NPC1 2887/4885RAB9A 3507/4885 |
| US-20210179548-A1 | METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE | CPS1, CA7, CA4 | FAAH 563/4885NPC1 2143/4885RAB9A 3532/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | FAAH 847/4885NPC1 2887/4885RAB9A 3507/4885 |
| US-20230021574-A1 | METHOD FOR PRODUCING ISOCYANATE | CPS1, IDH3A, ALKBH3 | FAAH 600/4885NPC1 2696/4885RAB9A 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.